A Study of Nemtabrutinib (MK-1026) (ARQ 531) in Participants With Selected Hematologic Malignancies
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
This study aims to evaluate the safety, tolerability, pharmacodynamic, and pharmacokinetic
(PK) of nemtabrutinib (formerly ARQ 531) tablets in selected participants with relapsed or
refractory hematologic malignancies. No formal hypothesis testing will be performed for this
study.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
ArQule ArQule, Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)